A multi-center, dose-escalation, phase I trial is ongoing to assess the maximum tolerated dose and the pharmacodynamic activity of the combination RO5126766 plus the FAK inhibitor defactinib in advanced solid tumors including KRAS+ NSCLC (NCT03875820). This evidence concerns the gene KRAS and non-small cell lung carcinoma.